Novel Therapeutic Modalities for Hepatic Diseases

2001 ◽  
pp. 17-29
Author(s):  
Henning Wege ◽  
Jian Wu ◽  
Mark A. Zern
Keyword(s):  
Therapeutic Modalities ◽  
Hepatic Diseases ◽  
Novel Therapeutic

Novel Techniques for Trigeminal Neuralgia Including Trigeminal Neurostimulators

2018 ◽  
pp. 118-138
Author(s):  
Arvin R. Wali ◽  
Christian Lopez ◽  
Peter Abraham ◽  
Michael G. Brandel ◽  
David R. Santiago-Dieppa ◽  
...  
Keyword(s):  
Trigeminal Neuralgia ◽  
Facial Nerve ◽  
Patient Selection ◽  
Microvascular Decompression ◽  
Published Data ◽  
Gasserian Ganglion ◽  
Therapeutic Modalities ◽  
Trigeminal Nerve Stimulation ◽  
Surgical Options ◽  
Novel Therapeutic

Several innovative surgical options for the management of trigeminal neuralgia have emerged over the past 40 years. In addition to microvascular decompression, other techniques have been introduced for the treatment of trigeminal neuralgia and facial nerve pain. This chapter describes the following novel therapeutic modalities: endoscopic microvascular decompression, radiosurgery, radiofrequency, thermocoagulation, glycerol rhizotomoy, balloon compression, Gasserian ganglion stimulation, and subcutaneous trigeminal nerve stimulation. For each of these techniques, this chapter provides a description of the procedure, criteria for patient selection, and discusses published data regarding patient outcomes.

scholarly journals Development of Immunopathogenesis Strategies to Treat Behçet’s Disease

2012 ◽  
Vol 2012 ◽  
pp. 1-7 ◽  
Author(s):  
Osman Köse
Keyword(s):  
Molecular Structure ◽  
Biologic Agents ◽  
Treatment Modalities ◽  
The Novel ◽  
Therapeutic Modalities ◽  
Novel Treatment ◽  
Unclear Etiology ◽  
Antigen Presenting ◽  
Disease Understanding ◽  
Novel Therapeutic

Behçet disease is a chronic relapsing vasculitis with unclear etiology and immunopathogenesis. Antigenic stimuli, antigen presenting cells, T cells, monocyte, and neutrophil and endothelial cells are major parts of the pathology of the disease. Understanding of the new pathogenic mechanisms based on molecular structure of the disease helps us in improving the novel therapeutic modalities. These drugs target specific and nonspecific inhibition of the immun system. These therapies include biologic agents, new topical and systemic immunosuppressants, tolerizing agents, and immunoablation. Novel treatment will be promising to treat the especially recalcitrant cases to conventional therapy. In this paper, new aspect of the immunopathogenesis of Behçet’s diseases and novel treatment modalities will be discussed.

scholarly journals Novel therapeutic modalities for children with spasticity

2021 ◽  
Vol 5 (10) ◽  
pp. 630-635
Author(s):  
D.A. Krasavina ◽  
◽  
Yu.I. Ivanov ◽  
◽  
Keyword(s):  
Cerebral Palsy ◽  
Botulinum Toxin ◽  
Botulinum Toxin Type A ◽  
Type A ◽  
Botulinum Toxin Type ◽  
Safety And Efficacy ◽  
Surgical Interventions ◽  
Therapeutic Modalities ◽  
Reference Preparation ◽  
Novel Therapeutic

Background: early treatment using botulinum toxin type A (BTA) postpones or even prevents contractures and osteoarticular deformations and, therefore, surgical interventions in children with cerebral palsy (CP). Expansion of age groups and conditions to prescribe BTA is the primary trend of current studies. Aim: to assess the safety and efficacy of Relatox® in children aged 2–6 years with spastic CP. Patients and Methods: this simple blind randomized comparative study (2018–2019) enrolled 100 children aged 2–6 years with spastic CP. According to the study protocol, Relatox® (n=51) or reference preparation (n=49) was injected into spastic muscles. Each group included two subgroups (predominant involvement of the muscles of the upper or lower extremities). Topical and systemic reactions were evaluated immediately after injection. Over the follow-up (after 2, 4, 8, and 12 weeks after injections), muscle tonus using Modified Ashworth Scale (MAS) and pain severity using a 10-point visual analogue scale were assessed. Results: maximum total doses of botulinum toxin per injection session for both preparations were 60 to 200 units. The efficacy of both preparations was similar (p>0.05). Single self-limited mild and moderate topical and systemic adverse reactions typical for botulinum toxin were reported in both groups. Conclusions: the safety and efficacy of Relatox® are similar to these of reference preparation. Antispastic effect for muscles of the upper extremities was demonstrated, thereby allowing for expanding indications for Relatox®. Inclusion of the maximum number of spastic muscles in the protocol of injection session provided a full motor habilitation/rehabilitation of children. KEYWORDS: botulinum toxin type A, cerebral palsy, spasticity, efficacy, safety. FOR CITATION: Krasavina D.A., Ivanov Yu.I. Novel therapeutic modalities for children with spasticity. Russian Medical Inquiry. 2021;5(10):630–635 (in Russ.). DOI: 10.32364/2587-6821-2021-5-10-630-635.

scholarly journals Nucleic Acid Drugs—Current Status, Issues, and Expectations for Exosomes

Cancers ◽  
2021 ◽  
Vol 13 (19) ◽  
pp. 5002
Author(s):  
Yoji Yamada
Keyword(s):  
Nucleic Acid ◽  
Small Molecule ◽  
Viral Infections ◽  
Genetic Disorders ◽  
Clinical Status ◽  
Lipid Nanoparticles ◽  
Current Status ◽  
Nucleic Acid Therapeutics ◽  
Therapeutic Modalities ◽  
Novel Therapeutic

Nucleic acid drugs are being developed as novel therapeutic modalities. They have great potential to treat human diseases such as cancers, viral infections, and genetic disorders due to unique characteristics that make it possible to approach undruggable targets using classical small molecule or protein/antibody-based biologics. In this review, I describe the advantages, classification, and clinical status of nucleic acid therapeutics. To date, more than 10 products have been launched, and many products have been tested in clinics. To promote the use of nucleic acid therapeutics such as antibodies, several hurdles need to be surmounted. The most important issue is the delivery of nucleic acids and several other challenges have been reported. Recent advanced delivery platforms are lipid nanoparticles and ligand conjugation approaches. With the progress of exosome biology, exosomes are expected to contribute to the solution of various problems associated with nucleic acid drugs.

Challenges in the Discovery of Novel Therapeutic Agents in Cancer

2020 ◽  
Vol 20 (12) ◽  
pp. 931-932
Author(s):  
Ganji Purnachandra Nagaraju ◽  
Mohammad Amjad Kamal
Keyword(s):  
Cancer Survival ◽  
Therapeutic Agents ◽  
Cancer Microenvironment ◽  
Therapeutic Approaches ◽  
Patient Death ◽  
Therapeutic Modalities ◽  
Traditional Therapies ◽  
Therapeutic Compounds ◽  
Therapeutic Pressure ◽  
Novel Therapeutic

One of the major challenges currently facing cancer therapy is the development of drug resistance either intrinsically or as a result of treatment. Treatment evasion is mediated by an intricate web of signalling cascades and adaptations caused by selective therapeutic pressure, leading to metastatic spread and patient death. Hence, discovering and designing novel therapeutic compounds and regimens based on specific alterations in the cancer microenvironment and capable of overcoming resistance to traditional therapies is necessary to improve cancer survival outcomes. These new therapeutic modalities should exhibit improved solubility, penetration capacity and bioavailability in the tumor microenvironment as well as enhanced target specificity compared to old generation compounds. The success of this endeavour will contribute to the advent of precision medicine leading to personalized therapeutic approaches for patients.

scholarly journals Chordoma: A Review and Differential Diagnosis

2021 ◽  
Author(s):  
Veronica Ulici ◽  
Jesse Hart
Keyword(s):  
Differential Diagnosis ◽  
Targeted Therapy ◽  
Correct Diagnosis ◽  
Experimental Studies ◽  
Malignant Neoplasm ◽  
Axial Skeleton ◽  
High Rate ◽  
Malignant Neoplasms ◽  
Therapeutic Modalities ◽  
Novel Therapeutic

Context.— Chordomas are uncommon malignant neoplasms with notochordal differentiation encountered by neuropathologists, bone/soft tissue pathologists, and general surgical pathologists. These lesions most commonly arise in the axial skeleton. Optimal therapy typically involves complete surgical resection, which is often technically difficult owing to the anatomic location, leading to a high rate of recurrence. Lesions have been generally resistant to radiation and chemotherapy; however, experimental studies involving targeted therapy and immunotherapy are currently underway. Objective.— To summarize the clinical and pathologic findings of the various types of chordoma (conventional chordoma, dedifferentiated chordoma, and poorly differentiated chordoma), the differential diagnosis, and recent advances in molecular pathogenesis and therapeutic modalities that are reliant on accurate diagnosis. Data Sources.— Literature review based on PubMed searches containing the term “chordoma” that address novel targeted and immunomodulatory therapeutic modalities; ongoing clinical trials involved in treating chordoma with novel therapeutic modalities identified through the Chordoma Foundation and ClinicalTrials.gov; and the authors' practice experience combined with various authoritative texts concerning the subject. Conclusions.— Chordoma is a clinically and histologically unique malignant neoplasm, and numerous diagnostic considerations must be excluded to establish the correct diagnosis. Treatment options have largely been centered on surgical excision with marginal results; however, novel therapeutic options including targeted therapy and immunotherapy are promising means to improve prognosis.

Sign in / Sign up

Export Citation Format

Share Document